13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumab
Francesco Jacopo Romano(Federico II University Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Nadia Corcione(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Consiglia Russo(Ospedale Antonio Cardarelli), Carmela Barbato(Ospedale Antonio Cardarelli), Carlo Santoriello(Ospedale Antonio Cardarelli), Antonio Russo, Gianluca Guggino(Ospedale Antonio Cardarelli), Gianfranco De Dominicis, Giuseppe Failla(Azienda di Rilievo Nazionale ed Alta Specializzazione), Severo Campione(Federico II University Hospital), A. Tinto(Ospedale Antonio Cardarelli), Luciano Moccia(Ospedale Antonio Cardarelli), Riccardo Ronga(Ospedale Antonio Cardarelli), Fausto De Michele(Ospedale Antonio Cardarelli), Dario Arundine(Ospedale Antonio Cardarelli), Antonio Starace(Ospedale Antonio Cardarelli), L Romano(Ospedale Antonio Cardarelli), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), Antonio Raucci
Cited by 0
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180